β-Blockers and the Rate of Chronic Obstructive Pulmonary Disease Exacerbations.

Conclusions: Based on the limited number of studies that address β-blocker use in COPD, it appears that exacerbations are not increased and may be decreased. A randomized, placebo-controlled trial is in progress to possibly provide more definitive answers to this question. Until the trial is complete, β-blockers should not be withheld in COPD patients who have concurrent cardiovascular conditions, especially where there is a mortality benefit. PMID: 31271049 [PubMed - as supplied by publisher]

https://www.ncbi.nlm.nih.gov/pubmed/31271049?dopt=Abstract

Source: The Annals of Pharmacotherapy - July 3, 2019 Category: Drugs & Pharmacology Authors: Mersfelder TL, Shiltz DL Tags: Ann Pharmacother Source Type: research